Bio-Tissue Highlights Publication of DREAM Study

Source: Bio-Tissue

Bio-Tissue highlighted the publication of the Dry Eye Amniotic Membrane (DREAM) study in Clinical Ophthalmology.[1] This retrospective study was conducted at 10 clinical sites in the United States, led by Marguerite McDonald, MD, and Hosam Sheha, MD. It demonstrates that a single application of self-retained cryopreserved amniotic membrane (cAM) (PROKERA Biotissue, Miami) can accelerate the recovery of corneal surface and help reduce signs and symptoms of DED for an extended period of at least three months.

These results are consistent with another prospective study that showed that this lasting effect is correlated with corneal nerve regeneration as evidenced by an increase in corneal nerve density and improved corneal sensitivity.[2]

“The clinical evidence presented in DREAM continues to further establish the effectiveness of cryopreserved amniotic membrane in supporting healing in patients, and our commitment to provide tissue products that address the entire ocular surface disease spectrum,” Adrian Roji, Chief Commercial Officer of parent company TissueTech, said in a company news release. “Our cryopreserved amniotic tissue supports the healing of the ocular surface, and is also promising with respect to corneal nerve integrity.”

Bio-Tissue utilizes its proprietary CryoTek process, a cryopreservation technology, to preserve the biological and structural integrity of the natural tissue. Published studies have demonstrated that the CryoTek process provides an allograft that is essentially equivalent to fresh tissue.

  1.  McDonald M, Sheha H, Tighe S, et al. Treatment Outcomes in the DRy Eye Amniotic Membrane (DREAM) Study. Clinical Ophthalmology 2018: 12, 677-81.2.  
  2. John T, Tighe S, Sheha H, et al. Rock, “Corneal Nerve Regeneration after Self-Retained Cryopreserved Amniotic Membrane in Dry Eye Disease” The Journal of Ophthalmology, August 2017

Related Content